VGR-R01

DRUG4 trials

Sponsors

Beijing Tongren Hospital, Shanghai Vitalgen BioPharma Co., Ltd.

Conditions

Bietti Crystalline DystrophyInherited Retinal Diseases

Early Phase 1

Safety and Tolerability of VGR-R01 in Patients With Bietti Crystalline Dystrophy

Beijing Tongren HospitalBietti Crystalline Dystrophy

Start: 2022-09-15End: 2024-05-31Target: 3Updated: 2022-11-09

Phase 1

Safety and Tolerability of VGR-R01 for Patients With Bietti Crystalline Dystrophy

Active, not recruitingNCT05694598

Shanghai Vitalgen BioPharma Co., Ltd.Bietti Crystalline Dystrophy

Start: 2023-03-27End: 2028-09-13Target: 12Updated: 2025-12-24

A Safety Study of Contralateral Eye Dosing of VGR-R01 in Participants With Bietti's Crystalline Dystrophy (BCD)

Not yet recruitingNCT07586306

Shanghai Vitalgen BioPharma Co., Ltd.Bietti Crystalline Dystrophy

Start: 2026-06-01End: 2031-07-31Target: 15Updated: 2026-05-14

Phase 3

Study to Evaluate the Efficacy and Safety of VGR-R01 Gene Therapy in Patients With Bietti Crystalline Dystrophy

Active, not recruitingNCT06699108

Shanghai Vitalgen BioPharma Co., Ltd.Bietti Crystalline Dystrophy, Inherited Retinal Diseases

Start: 2024-12-13End: 2027-06-30Target: 45Updated: 2025-12-24

Related Papers

Preclinical studies of an AAV8-CYP4V2 gene therapy VGR-R01 for the treatment of Bietti crystalline dystrophy

Molecular Therapy — Methods & Clinical Development2025-04-041 citations